TMDX

Healthcare Medical Devices

TransMedics Group, Inc.

$80.28
-2.69 -3.24% today

Price History

Not enough data

Key Stats

Market Cap
2.78B
Avg Volume
818,843
P/E (TTM)
20.80
EPS
$3.86
52W High
$156.00
52W Low
$60.11
Div. Yield
0.0%

Analyst Ratings

Buy
2
Str Buy
6
Buy
4
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
35.47
P/B Ratio
5.37
P/S Ratio
4.15
EV/EBITDA
28.30
EV/Revenue
4.90
PEG Ratio
0.68

Margins

Gross Margin 58.7%
Operating Margin 12.5%
Net Margin 22.7%
EBITDA Margin 17.3%

Growth & Returns

Revenue Growth (YoY)
20.7%
Earnings Growth (YoY)
(55.8%)
Earnings Growth (QoQ)
(57.9%)
Return on Equity
36.3%
Return on Assets
4.3%

Liquidity & Leverage

Current Ratio
6.63
Quick Ratio
5.87
Debt / Equity
1.67
Total Cash
472.68M
Total Debt
867.72M

About

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com